Methods of screening for compounds for treating muscular dystrophy using human ALPHA7 integrin mRNA translation regulation
US9376725B1 · kind B1 · utility
0Cited by
51References
16Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 24, 2014 |
| Grant date | Jun 28, 2016 |
| Priority date | — |
| Expiry date | Jul 25, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12Q2600/136
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention provides compounds and assays for the identification and validation of compounds for use in the treatment of muscular mystrophy (MD), or a form thereof, in which said compounds increase the post-transcriptional expression of a target gene (i.e., mIGF1, ITGA7, or UTRN).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.